Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.

Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.

Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.